Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.

Diabetes Obes Metab · 2022 · PMC9321749 · PMID 35373893

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

A real‐world study has also reported a significant trend for greater weight reduction with liraglutide in patients with higher baseline BMI. 25 In the present analyses with oral semaglutide, body weight reductions were seen across BMI subgroups, with a general pattern towards greater reductions in body weight in patients with higher baseline BMI within several of the PIONEER trials.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.